Topic: triple-negative breast cancer
Tecentriq is the only drug in its class with a green light in previously untreated triple-negative breast cancer, but Merck plans to change that.
Despite the pandemic, Immunomedics has raised some extra money to help Trodelvy's launch, expand its clinical programs and scale up manufacturing.
Immunomedics weathered a nixed licensing deal, two manufacturing slapdowns, a complete response letter and a C-suite overhaul to win its new FDA nod.
Merck’s Keytruda may have stumbled early in its candidacy as a triple-negative breast cancer treatment, but those days seem to be behind it.
Merck and Roche are no strangers to sparring with their I-O meds Keytruda and Tecentriq, but in TNBC, Keytruda's latest data take the prize.
Keytruda's U.S. NSCLC sales might start to fall as soon as early 2020, one analyst says, as I-O rivals eat into its share based on recent successes.
Wall Street analysts pressed Merck for details about whether Keytruda can maintain strong growth as it faces rivals in lung and breast cancer.
Riding high on FDA and EU approvals in triple-negative breast cancer, Roche’s Tecentriq hoped for a win from NICE. The drugmaker didn’t get it.
Merck’s Keytruda may have come up short in metastatic TNBC over the weekend, but in the pre-surgery setting, it posted a first-of its-kind win.